Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Summary

This phase II trial studies the effects of binimetinib and encorafenib in treating patients with melanoma that has spread to the central nervous system (metastases). Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and encorafenib may help control melanoma that has spread to the brain.

Timeline

Start

2021-12-27

Primary completion

2027-02-02

Completion

2027-02-02

Publications

• Corradi G, De Martino S, Rinaldi A, Siepe G, Marchese PV, Melotti B, Comito F. Rapid radiological response of leptomeningeal carcinosis and prolonged survival to encorafenib and binimetinib in BRAF-mutated melanoma. Anticancer Drugs. 2025 Sep 1;36(8):691-693. doi: 10.1097/CAD.0000000000001737. Epub 2025 May 30.

Drugs

Indications